Peptisource

LL-37 5mg

LL-37, the sole antimicrobial peptide in the human body, belongs to the catholicizing family, consists of 37 amino acids, and features an amphipathic α-helical structure. Primarily synthesized by neutrophils, it can also be secreted by macrophages, monocytes, keratinocytes, and other cell types. LL-37 plays a pivotal role in human immune defense, exhibiting multiple biological functions including broad-spectrum antibacterial activity, immunomodulation, and promotion of wound healing. It effectively inhibits gram-positive bacteria, gram-negative bacteria, fungi, and viruses, enhances the body’s anti-infective capacity)by regulating chemotaxis of immune cells and secretion of inflammatory factors, and stimulates angiogenesis and tissue repair simultaneously. With advantages such as broad-spectrum antibacterial activity, low propensity for drug resistance, low cytotoxicity, and immunomodulatory functions, LL-37 demonstrates substantial potential, particularly in addressing antibiotic resistance. Research on LL-37 not only provides novel insights for developing new antibacterial and immunotherapeutic agents but also promotes in-depth exploration in the field of antimicrobial peptides, offering critical scientific evidence for solving issues related to infectious diseases, chronic wounds, and autoimmune disorders.

Spec: 5mg
Packaging: 1kits（10Vials）
$150USD
1

▎LL-37 Overview


LL-37, the sole antimicrobial peptide in the human body, belongs to the catholicizing family, consists of 37 amino acids, and features an amphipathic α-helical structure. Primarily synthesized by neutrophils, it can also be secreted by macrophages, monocytes, keratinocytes, and other cell types. LL-37 plays a pivotal role in human immune defense, exhibiting multiple biological functions including broad-spectrum antibacterial activity, immunomodulation, and promotion of wound healing. It effectively inhibits gram-positive bacteria, gram-negative bacteria, fungi, and viruses, enhances the body’s anti-infective capacity)by regulating chemotaxis of immune cells and secretion of inflammatory factors, and stimulates angiogenesis and tissue repair simultaneously. With advantages such as broad-spectrum antibacterial activity, low propensity for drug resistance, low cytotoxicity, and immunomodulatory functions, LL-37 demonstrates substantial potential, particularly in addressing antibiotic resistance. Research on LL-37 not only provides novel insights for developing new antibacterial and immunotherapeutic agents but also promotes in-depth exploration in the field of antimicrobial peptides, offering critical scientific evidence for solving issues related to infectious diseases, chronic wounds, and autoimmune disorders.